Please assess the completion status of the following clinical trial:

Trial Title: Curcumin + Aminosalicylic Acid (5ASA) Versus 5ASA Alone in the Treatment of Mild to Moderate Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of UC as confirmed by endoscopic or histologic criteria as established by RomeIII~* Disease activity score of \>5 and ≤13 according to the Simple clinical colitis activity index (SCCAI)~* Patient on stable 5 ASA medication dose for at least 4 weeks prior to inclusion~* Patients who receive immunosuppressant or biological therapy (azathioprine, 6-mercaptopurine, infliximab or methotrexate) must be on stable dose for at least 3 months prior to inclusion~* Patients who receive topical therapy (5ASA or steroidal), must be on stable dose for a least 2 weeks prior to inclusion~* Patient had hemoglobin of \>10 g/dl.~* Able and willing to give written consent~Exclusion Criteria:~* Patient with renal or liver disease, sever cardiovascular disease, chronic pancreatitis, diabetes mellitus or gallstone.~* Patient with laboratory abnormalities indicating anemia (hemoglobin \<10), leucopenia, thrombocytopenia, abnormal coagulation.~* Patient with infection, sepsis or pneumonia.~* Pregnant or nursing women.~* Unable or unwilling to receive CURCUMIN therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Treatments arm (Type: ACTIVE_COMPARATOR): Patients allocated for this arm will receive 5ASA medication (as advised by their treating physician) + 3 capsules (total of 820 mg each,containing 500 mg curcumin ) curcumin twice daily after meals.
- Control arm (Type: PLACEBO_COMPARATOR): Patients allocated to this arm will receive 5ASA medication (as advised by their treating physician) + 3 capsules (820gr each) of placebo twice a day after meals.

Based on this trial design, predict the completion outcome and termination type (if applicable).